New president of Merck Vaccines
This article was originally published in Scrip
Merck & Co has named Dr Julie Gerberding president of Merck Vaccines, effective January 25th. She will be responsible for the commercialisation of the company's portfolio of vaccines and accelerating Merck's ongoing efforts to broaden access to its vaccines in the developing world. Dr Gerberding led the US Centers for Disease Control and Prevention as director from 2002-09.
You may also be interested in...
Two leading, independent bodies of French scientists, doctors and pharmacists are calling for OTC drugs containing pseudoephedrine to be reverse-switched to prescription-only status over safety fears.
COVID-19 has shifted consumer health behaviour towards prevention and general wellbeing. However, finding out what consumers actually want and need is still the essence of good OTC innovation, according to Stada Arzneimittel's new vice president of consumer healthcare product development Steve Makin.
Swiss biotech Molecular Partners will receive upfront payment of CHF 60m, including equity.